Radius Health

209 articles with Radius Health

• Radius Health Business Update - July 27, 2021

  7/27/2021

  New patient adds for the U.S. TYMLOS business continue to grow. New TYMLOS patients in Q2, 2021 were up over 40% vs. the same period in 2020.

• 

  Clinical Catch-Up: July 19-23

  7/26/2021

  It was another busy week for clinical trial updates. Here’s a look at some including Mesoblast Limited, CytoDyn, Magenta Therapeutics and more.

• Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study

  7/22/2021

  Radius Health, Inc. (“Radius” or the “Company”) (NASDAQ: RDUS) today announced that it has recently received the written meeting minutes from a June Type C meeting held with the U.S. Food and Drug Administration (“FDA”) regarding RAD011, a synthetic cannabidiol oral solution.

• Radius Health to Announce Second Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Thursday, August 5, 2021

  7/20/2021

  Radius Health, Inc. (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Thursday, August 5, 2021.

• Radius Health, Inc.: First Quarter 2021 Results

  5/7/2021

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial results for the first quarter ended March 31, 2021.

• Radius Health Business Update

  4/22/2021

  Radius Health, Inc., provided the following business update. The Company’s first quarter 2021 earnings will take place on Friday, May 7 at 8:30am EST.

• Radius Health to Announce First Quarter 2021 Financial Results, Host Conference Call and Live Webcast on Friday, May 7, 2021

  4/20/2021

  Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Friday, May 7, 2021.

• Radius Health Provides Update on Abaloparatide

  3/24/2021

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided an update on the abaloparatide asset including regulatory progress as well as U.S. commercial activity.

• Radius Health, Inc. Announces $175 Million Financing Transaction

  3/3/2021

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that the Company has entered into amended and restated credit facilities in the aggregate principal amount of $175 million, consisting of a $150 million term loan, which includes a cashless conversion of $25 million in existing term loans, and a $25 million revolving credit facility

• Radius Health, Inc.: Fourth Quarter and Full Year Results - Feb 25, 2021

  2/25/2021

  Radius Health, Inc., reported its financial results for the fourth quarter ended December 31, 2020 as well as full year 2020 results.

• Radius Health to Present at 10th Annual SVB Leerink Global Healthcare Conference

  2/17/2021

  Radius Health, Inc., announced that it will provide a corporate update at the 10th Annual SVB Leerink Global Healthcare Conference at 10:40 a.m. ET on Thursday, February 25, 2021.

• Radius Health to Announce Fourth Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday, February 25, 2021

  2/16/2021

  Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter financial results on Thursday, February 25, 2021. The Company will host a conference call and live audio webcast at 8:30 a.m. ET that day to discuss the results and provide a company update.

• Radius Health, Inc. Announces Acquisition of Orphan Disease Program

  1/6/2021

  RAD011 is a pivotal-trial ready synthetic cannabidiol oral solution with potential utilization in multiple endocrine and metabolic orphan diseases

• Radius Health, Inc. Provides Business Update

  12/15/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since October 2020.

• Radius Health, Inc.: Third Quarter 2020 Operating Results

  11/5/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today reported its financial and operating results for the third quarter ended September 30, 2020, and provided a business update.

• Radius Health, Inc.: Progress Since May 2020

  10/21/2020

  Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) provided a general business update on progress made since May 2020.

• 

  BioSpace Movers & Shakers, Oct. 9

  10/9/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Peter A. Schwartzman Joins Radius Health, Inc.Schwartzman joins the newly formed Capital, Strategy, & Transactions Group

  10/6/2020

  Radius Health, Inc. announced that Peter A. Schwartzman is joining the company as Vice President in the newly formed Capital, Strategy and Transactions Group. Peter, as part of the group, will report to Kelly Martin, CEO of Radius.

• Radius Health Divests RAD 140 Program to Ellipses Pharma

  10/1/2020

  Radius Health, Inc. announced that the company has successfully sold its second oncology pipeline asset – RAD 140 - to Ellipses Pharma Limited, completing Radius’s divestment of its oncology assets.

• Radius Health Provides Business Update - Sep 24, 2020

  9/24/2020

  Radius Health, Inc., announced that Jose Carmona will be stepping down as Chief Financial Officer of Radius Health, Inc., with immediate effect.